8 results about "FOOD EFFECT" patented technology

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

The present application relates to a lurasidone hydrochloride pharmaceutical composition and a preparation method thereof. The present application discloses a lurasidone hydrochloride pharmaceutical composition, which comprises lurasidone hydrochloride and a stabilizer, wherein the lurasidone hydrochloride is in nanoscale. The prepared lurasidone hydrochloride pharmaceutical composition can improve the solubility and bioavailability of the drug, and reduce the influence of food effect. The preparation method of the present application is simple in operation, low in production cost and easy to realize industrialized scale-up production.

This invention provides a nilotinib capsule with reduced food-related effects and its preparation method, addressing the shortcomings of existing products. It solves the problem that existing products require avoiding the influence of food. This invention innovatively improves the dissolution and release of the drug in media with different pH values ​​by adding a specific combination of acidic pH adjusters and solubilizers to the formulation. This innovative formulation adjustment solves the problem of food affecting the release and absorption of this product, and improves the time-limited nature of administration. Therefore, this invention has great application value and promising prospects for promotion.

Amorphous solid dispersions of nilotinib fumarate or nilotinib tartrate are provided, as well as pharmaceutical compositions thereof, wherein the compositions exhibit enhanced bioavailability in the fasted state. Preferably, the compositions may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Cmax, AUC0-t and / or AUC0-infinity) of nilotinib, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

This invention discloses a briceceran sustained-release tablet and its preparation method, belonging to the field of pharmaceutical formulations. This invention aims to solve the problems of food effect, release instability, and processability issues associated with briceceran sustained-release tablets. Technical solution: A tablet-within-a-tablet structure is adopted, with the sustained-release core containing a composite hydroxypropyl methylcellulose (high / medium viscosity mixture) and micronized ethyl cellulose, and the immediate-release outer layer containing a disintegrant; the preparation includes ethanol granulation and compression steps. Technical effects: Achieves stable drug release over 24 hours, with a postprandial / fasting release difference of <3%, avoiding dose dumping, while improving flowability and hardness by 53%, suitable for industrial production.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

Provided herein are amorphous solid dispersions of nilotinib fumarate or nilotinib tartrate, and pharmaceutical compositions thereof, wherein the compositions exhibit enhanced bioavailability in the fasted state. Preferably, the compositions can be orally administered to a patient in the fed or fasted state with a reduction or elimination of food effect. Preferably, there is no substantial difference in the pharmacokinetic parameters (e.g., C max , AUC 0‑t , and / or AUC 0‑无穷大 ) of nilotinib following oral administration of the pharmaceutical composition, whether the pharmaceutical composition is administered to the subject in the fed or fasted state.